Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components

G. Sgouros, M. Stabin, Y. Erdi, G. Akabani, C. Kwok, A. B. Brill, B. Wessels

Research output: Contribution to journalReview articlepeer-review

Abstract

Hematologic toxicity limits the radioactivity that may be administered for radiolabeled antibody therapy. This work examines approaches for obtaining biodistribution data and performing dosimetry when the administered antibody is known to bind to a cellular component of blood, bone, or marrow. Marrow dosimetry in this case is more difficult because the kinetics of antibody clearance from the blood cannot be related to the marrow. Several approaches for obtaining antibody kinetics in the marrow are examined and evaluated. The absorbed fractions and S factors that should be used in performing marrow dosimetry are also examined and the effect of including greater anatomical detail is considered. The radiobiology of the red marrow is briefly reviewed. Recommendations for performing marrow dosimetry when the antibody binds to the marrow are provided. (C) 2000 American Association of Physicists in Medicine.

Original languageEnglish (US)
Pages (from-to)2150-2164
Number of pages15
JournalMedical physics
Volume27
Issue number9
DOIs
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components'. Together they form a unique fingerprint.

Cite this